- Home
- PROK vs FLL Comparison
PROK vs FLL Comparison
Compare PROK & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- FLL
- Stock Information
- Founded
- PROK 2015
- FLL 1987
- Country
- PROK United States
- FLL United States
- Employees
- PROK N/A
- FLL N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- FLL Hotels/Resorts
- Sector
- PROK Health Care
- FLL Consumer Discretionary
- Exchange
- PROK Nasdaq
- FLL Nasdaq
- Market Cap
- PROK 186.8M
- FLL 166.6M
- IPO Year
- PROK N/A
- FLL 1993
- Fundamental
- Price
- PROK $1.05
- FLL $4.27
- Analyst Decision
- PROK Buy
- FLL Strong Buy
- Analyst Count
- PROK 5
- FLL 4
- Target Price
- PROK $4.50
- FLL $6.25
- AVG Volume (30 Days)
- PROK 546.9K
- FLL 148.3K
- Earning Date
- PROK 03-21-2025
- FLL 03-06-2025
- Dividend Yield
- PROK N/A
- FLL N/A
- EPS Growth
- PROK N/A
- FLL N/A
- EPS
- PROK N/A
- FLL N/A
- Revenue
- PROK N/A
- FLL $292,065,000.00
- Revenue This Year
- PROK N/A
- FLL $13.51
- Revenue Next Year
- PROK N/A
- FLL $8.46
- P/E Ratio
- PROK N/A
- FLL N/A
- Revenue Growth
- PROK N/A
- FLL 21.16
- 52 Week Low
- PROK $0.98
- FLL $3.77
- 52 Week High
- PROK $4.44
- FLL $5.94
- Technical
- Relative Strength Index (RSI)
- PROK 23.63
- FLL 30.92
- Support Level
- PROK $0.98
- FLL $5.10
- Resistance Level
- PROK $1.32
- FLL $5.04
- Average True Range (ATR)
- PROK 0.11
- FLL 0.28
- MACD
- PROK -0.04
- FLL -0.13
- Stochastic Oscillator
- PROK 10.61
- FLL 17.11
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.